CYduct Diagnostics, Inc. engages in the development and marketing of technology, applications, medical devices, and procedural techniques for screening, diagnosis, treatment, and management of disease and medical conditions. The company is headquartered in Westport, Connecticut. The company went IPO on 2001-06-21. The firm focuses on the women's healthcare market, primarily breast healthcare and wellness. The company is focused on breast health and wellness through testing methods. The company focuses to provide a technology platform that includes evidence-based personalized breast health risk assessment testing. The firm serves medical schools, hospitals and physicians to develop medical devices and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.
Panacea Life Sciences Holdings Inc 最大收入来源是 Hemp-derived Cannabinoid,在最近的收益报告中收入为 910,518。就地区而言, United States 是 Panacea Life Sciences Holdings Inc 的主要市场,收入为 910,518。
Cyduct Diagnostics Inc 是否盈利?
否,根据最新的财务报表,Panacea Life Sciences Holdings Inc 的净亏损为 $0